AMYT Amryt Pharma Plc

TIDMAMYT

Amryt Pharma PLC

20 December 2017

20 December 2017

AIM: AMYT

ESM: AYP

Amryt Pharma plc

("Amryt" or the "Company")

Senior Management Team Appointment -

Vice-President of Global Distributor Markets

Amryt Pharma, a biopharmaceutical company focused on treatments for rare and orphan diseases, is pleased to announce the appointment of Patrick Jordan as Vice-President of Global Distributor Markets.

Patrick has worked in the pharmaceutical industry for the last 18 years, during which time he held senior roles at Pfizer and MSD (Merck & Co.) ("MSD"). He has significant experience across sales, marketing, business development, and general management, and been based in a number of global territories. Latterly, Patrick was the Managing Director of MSD's Saudi operations and before that served as MSD's Regional Managing Director of its Eastern Europe and North Africa business.

Patrick holds an MBA from Babson College, Massachusetts, together with an undergraduate Bachelor of Arts degree in Biochemistry/Molecular Biology from Boston University, in the USA.

Dr. Joe Wiley, Chief Executive Officer, commented:

"I am delighted to welcome Patrick to our senior management team as Vice-President of Global Distributor Markets. He takes up a new role at Amryt, which reflects the progress we are making as we focus on our expanding opportunities across global markets.

"Patrick's role includes supporting Amryt's recently announced entry into the Kingdom of Saudi Arabia, as well as our planned expansion into new territories in Central & Eastern Europe, Middle East, North Africa, and beyond."

Enquiries:

 
Amryt Pharma plc              C/o KTZ Communications 
Joe Wiley, CEO 
 Rory Nealon, CFO/COO 
 
                              +44 (0) 20 3178 
KTZ Communications             6378 
Katie Tzouliadis, Irene 
 Bermont-Penn, Emma Pearson 
 

About Amryt Pharma plc

(www.amrytpharma.com)

Amryt Pharma is a specialty pharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare or orphan diseases. The Company is building a diversified portfolio of commercially attractive, best-in-class, proprietary new drugs to help address some of these rare and debilitating illnesses for which there are currently no available treatments.

The Company holds an exclusive licence to sell Lojuxta (lomitapide) for adults, across the EU and other territories including the Middle East, North Africa, Turkey and Israel. Lojuxta is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia, which impairs the body's ability to remove LDL cholesterol ("bad" cholesterol) from the blood. This typically results in extremely high blood LDL cholesterol levels leading to aggressive and premature narrowing and blocking of arterial blood vessels. If left untreated, heart attack or sudden death may occur in childhood or early adulthood.

Amryt's lead drug candidate, AP101, is a potential treatment for Epidermolysis Bullosa ("EB"), a rare and distressing genetic skin disorder affecting young children for which there is currently no treatment. It is currently in Phase 3 clinical trials. The global market opportunity for EB is estimated to be in excess of EUR 1.3 billion.

Amryt's earlier stage product AP102 is focused on developing novel, next generation somatostatin analogue ("SSA") peptide medicines for patients with rare neuroendocrine diseases, where there is a high unmet medical need, including acromegaly and Cushing's disease.

The Company joined AIM and Dublin's ESM in April 2016 following the reverse takeover of Fastnet Equity PLC.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRATLBLTMBBBBPR

(END) Dow Jones Newswires

December 20, 2017 02:00 ET (07:00 GMT)

Amryt Pharma (LSE:AMYT)
Historical Stock Chart
From Apr 2024 to May 2024

Amryt Pharma (LSE:AMYT)
Historical Stock Chart
From May 2023 to May 2024